top of page
Image by CDC

Lixa exists to solve the global problem of antimicrobial resistance.

Our technologies are broadly applicable across human, animal, plant, marine and industrial applications.

Copy of Untitled Design (17).png

A moonshot to fix the broken antibiotic business model

By 2050, Antimicrobial Resistance (AMR) is forecast to have caused 39M deaths and US$100 trillion in economic loss (1).

​

80% of the US$71bn antibiotics market (2) are off-patent, generic drugs (3) - highly unusual in the pharmaceutical industry. 

​

Patented antibiotics are expensive, toxic, costly to develop (>AUS$1n) (4) and get shelved as "last resort" to avoid new superbugs emerging.

​

Antibiotics are essential but, intrinsically, evoke resistance. 

It's time to build on the foundations laid by antibiotics and multiply their effect with resistance breakers - towards a new antimicrobial paradigm. 

​

1) The Lancet, 2024

2) Precedence Research

3) Kållberg et al, 2021

4) Nature, 2024

Resistance is a multifaceted problem

Bacterial resistance is a growing issue, not only against antibiotic drugs but against biocides that control bacteria in our environment.

​

This resistance is exponentially increased by biofilms, a difficult to remove matrix or slime that prevents treatments from reaching their target. 

 

Our proprietary ingredients not only dismantle the biofilm but disable resistance mechanisms - targeting unmet needs in acute and chronic, planktonic and biofilm, resistant contaminations and infections. â€‹

Copy of Untitled Design (18).png
Picture1.jpg

35% of sepsis deaths associated with resistant bacteria

Acute infections and sepsis 

Picture2.jpg

US$34bn annual economic cost

40% additional fuel consumption

Marine fouling

wound.jpg

80% of chronic infections associated with bacterial biofilms

Chronic infections

Picture3.jpg

US$2.7T annual economic cost from bacterial associated corrosion

Industrial corrosion

Building on the foundations laid by existing antimicrobial technologies, we can now open new dimensions of treatment that multiply the effective antimicrobial arsenal, solve “untreatable” bacterial problems and simplify treatment regimes.
bottom of page